↓ Skip to main content

Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World

Overview of attention for article published in Frontiers in oncology, July 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World
Published in
Frontiers in oncology, July 2022
DOI 10.3389/fonc.2022.950266
Pubmed ID
Authors

Xiaowei Li, Zhigang Fu, Xiaoxia Chen, Kunkun Cao, Jiaming Zhong, Li Liu, Ning Ding, Xiaoli Zhang, Jian Zhai, Zengqiang Qu

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 17%
Student > Bachelor 1 8%
Unspecified 1 8%
Unknown 8 67%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 8%
Neuroscience 1 8%
Medicine and Dentistry 1 8%
Unknown 9 75%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2022.
All research outputs
#5,098,877
of 26,370,291 outputs
Outputs from Frontiers in oncology
#1,838
of 23,018 outputs
Outputs of similar age
#102,224
of 444,469 outputs
Outputs of similar age from Frontiers in oncology
#123
of 1,801 outputs
Altmetric has tracked 26,370,291 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,018 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 444,469 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 1,801 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.